Oxford BioTherapeutics Ltd. is a specialized biotechnology company focused on the development of innovative therapies for cancer patients. Founded in 2003 and currently active, the company operates from its headquarters in Oxford, United Kingdom, at Suite A, Second Floor, The Schrodinger Building, Heatley Road, OX4 4GE. Oxford BioTherapeutics specializes in the design, synthesis, and optimization of targeted therapies, primarily concentrating on Antibody-Drug Conjugates (ADCs), Immuno-oncology, T-Cell Engagers (TCE), and radiopharmaceuticals. The company’s core research efforts are geared towards addressing unmet needs in oncology, aiming to improve treatment efficacy and patient outcomes. The company’s strategic focus is on developing novel therapeutic modalities, leveraging advanced technologies and a dedicated team of scientists and researchers. Oxford BioTherapeutics is currently operating under the Visa of Global Business Mobility, with a Worker rating, indicating a commitment to continued growth and innovation within the biotechnology sector. The company’s international presence is currently limited, but actively pursuing strategic partnerships and collaborations to expand its reach.

Oxford BioTherapeutics Ltd. is a specialized biotechnology company focused on the development of innovative therapies for cancer patients. Founded in 2003 and currently active, the company operates from its headquarters in Oxford, United Kingdom, at Suite A, Second Floor, The Schrodinger Building, Heatley Road, OX4 4GE. Oxford BioTherapeutics specializes in the design, synthesis, and optimization of targeted therapies, primarily concentrating on Antibody-Drug Conjugates (ADCs), Immuno-oncology, T-Cell Engagers (TCE), and radiopharmaceuticals. The company’s core research efforts are geared towards addressing unmet needs in oncology, aiming to improve treatment efficacy and patient outcomes. The company’s strategic focus is on developing novel therapeutic modalities, leveraging advanced technologies and a dedicated team of scientists and researchers. Oxford BioTherapeutics is currently operating under the Visa of Global Business Mobility, with a Worker rating, indicating a commitment to continued growth and innovation within the biotechnology sector. The company’s international presence is currently limited, but actively pursuing strategic partnerships and collaborations to expand its reach.